Last reviewed · How we verify
Shigella sonnei 53G
At a glance
| Generic name | Shigella sonnei 53G |
|---|---|
| Sponsor | PATH |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
- Diarrhoea
- Headache
- Abdominal pain
- Decreased appetite
- Tachycardia
- Defaecation urgency
- Gastrointestinal sounds abnormal
- Pyrexia
- Chills
- Malaise
- Flatulence
- Dysentery
Key clinical trials
- Phase 2 Shigella Vaccine and Challenge (PHASE2)
- Shigella Sonnei 53G Human Infection Study in Kenyan Adults (PHASE1)
- Controlled Human Infection Model Challenge/Rechallenge (PHASE1)
- A Study to Evaluate the Efficacy, Safety and Immunogenicity of a Vaccine Designed to Protect Against Infection With Shigella Sonnei in Healthy Adults (PHASE2)
- Dose-Finding Study of Lyophilized Shigella Sonnei 53G Challenge Strain (PHASE1)
- Safety and Efficacy Study of WRSS1, a Shigella Sonnei Vaccine Candidate (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Shigella sonnei 53G CI brief — competitive landscape report
- Shigella sonnei 53G updates RSS · CI watch RSS
- PATH portfolio CI